tbuckley/cabot-search huggingface dataset:
Follow the guideline to improve abilities in diagnosis, treatment and management of Parkinson's disease at grassroots level
Authors: Dongdong Wu
Journal: BMJ (2020)

原发性帕金森病是一种隐匿起病、缓慢进展的神经变性病。结合基层医疗的特点和需求，首次制订了我国《帕金森病基层诊疗指南（2019年）》。本文特别对指南中的诊断步骤、治疗及基层管理等作出说明，便于基层医生理解和更方便地应用该指南。
CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.
Authors: Geralyn Carol Trudel, Angela J. Howes, Neelum Jeste, Jeffrey J. Tryon, Liang Xiu, Colleen Kane, Kerri Nottage
Journal: Journal of Clinical Oncology (2020)

TPS7565 Background: AML, the most common acute leukemia in adults, is a heterogeneous malignancy characterized by uncontrolled clonal expansion of hematopoietic progenitor cells. Median diagnosis age is ~67 yrs. Despite current therapies prognosis is poor with 5-yr OS ~25% for patients (pts) ≥65 yrs. For pts unable to receive intensive chemotherapy, survival rates are worse, indicating a critical need to develop better treatments. CD70 is expressed on &gt;95% of AML blasts harvested from newly diagnosed AML pts but not on normal hematopoietic stem cells nor most normal tissues. Cusatuzumab is a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in leukemia blast and stem cell cytotoxicity. As cusatuzumab and azacitidine target distinct pathways of myeloblast propagation, a combination may have a synergistic therapeutic effect and overcome treatment resistance. Initial data from a Phase I study (NCT03030612) with cusatuzumab (1–20 mg/kg) + standard dose azacitidine in AML pts ineligible for intensive chemotherapy showed no dose-limiting toxicity and a CR/CRi (CR with partial/incomplete hematologic recovery) in 10 of 12 pts (ASH 2019, Abs #234). This abstract describes a follow-on Phase II study (NCT04023526). Methods: CULMINATE is a 2-part study of cusatuzumab + azacitidine to determine the optimal dose of cusatuzumab (Table). Inclusion criteria: ≥18 yrs with de novo or secondary AML unfit for intensive therapy (≥75 or &lt;75 yrs with a comorbidity [i.e. ≥1 of: ECOG 2, severe cardiac/pulmonary or moderate hepatic impairment]). In Part 1, pts are randomized 1:1 to cusatuzumab 10 or 20 mg/kg (IV, on Days 3 and 17 of each 28-day cycle) + azacitidine (75 mg/m 2 SC or IV on Days 1–7). Data will be reviewed after 15, 30 and 50 pts are enrolled into each arm to select the cusatuzumab dose for the Part 2 expansion cohort in which efficacy and safety will be further evaluated. Follow-up continues until death, loss to follow-up or study end. The primary objective is to determine CR rate. Secondary objectives include rate of CRi/CRh, rate of MRD-negativity, ORR, time to and duration of response, pharmacokinetics, immunogenicity, transfusion independence and safety. Enrollment began in Sept 2019 and is currently two-thirds complete. Clinical trial information: NCT04023526 . [Table: see text]
The Temporal Association Cortex Plays a Key Role in Auditory-Driven Maternal Plasticity
Authors: Gen-ichi Tasaka, Libi Feigin, Ido Maor, Maya Groysman, Laura A. DeNardo, Jennifer K. Schiavo, Robert C. Froemke, Liqun Luo, Adi Mizrahi
Journal: Neuron (2020)
Research progress of intestinal flora in rheumatic immune diseases
Authors: Meijia Chen, Nan Shen
Journal: BMJ (2019)

Gut microbiota is composed of trillions of microorganisms inhabiting in the human gastrointestinal tract, profoundly influences many aspects of host physiology. The roles of gut microbiota have been investigated extensively in the gastrointestinal, endocrine, neurological, cardiovascular and immune systems. This article reviews the recent research progress on the function of microbes in healthy organisms, the common research methods for microbiota, and the roles of microbiota in rheumatic immune diseases. It is expected that gut microbiota would be a novel target of clinical diagnosis and treatment for rheumatic immune diseases.


Key words: 
Spondylitis, ankylosing; Arthritis, rheumatoid; Osteoarthritis; Gout; Gut microbiota
Treatment patterns in multiple myeloma: Real-world experience of the triple-class exposed (TCE) patient.
Authors: Nina Shah, Concetta Crivera, Maneesha Mehra, Iman Mohammadi, Karl M. Kilgore, Anny C. Wong, Sundar Jagannath
Journal: Journal of Clinical Oncology (2020)

e20543 Background: Recent advances in medical treatments have improved survival in multiple myeloma (MM), but relapse is a near certainty. TCE MM patients, i.e. treated with a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and anti-CD38, have been shown to have improved outcomes compared to patients with prior regimens, but patients who subsequently relapse have limited options. Objective: To describe the course of treatment in a real-world, TCE sample of patients with MM with an emphasis on treatments occurring after triple-exposure. Methods: This retrospective descriptive study used 100% Medicare Fee-for-Service claims data and Inovalon’s MORE² Registry, a commercial multi-payor claims database, to identify patients ≥ 18 years of age, newly diagnosed with MM in 2009-2017, and with ≥ 12 months continuous enrollment post-diagnosis. Patients with ≥ 3 lines of treatment (LOT) were considered relapsed/refractory MM (RRMM), and the TCE subset of those were analyzed in terms of number and timing of LOT. Results: 9534 patients were identified with RRMM and 29.2% (N = 2787) were TCE. TCE patients had a mean age of 70.8 and 50.1% were male. Treatment characteristics are shown in Table. Median number of LOT prior to TCE was 3, median time from diagnosis to TCE was 37 months, and 27.3% had a stem-cell transplant (SCT) prior to TCE. Patients had a median of 10 months of follow-up (range: 0-35) from end of the TCE LOT to end of follow-up. Nearly half (N = 1290, 46.3%) of the patients had at least 1 LOT post TCE, and 8% had at least 3. Over their entire post-TCE course of treatment, 826 (64%) received daratumumab, 443 (34%) received carfilzomib, and 356 (28%) received pomalidomide. 35.5% proceeded to penta-exposure (2 different PIs, 2 different IMiDs and an anti-CD38). Conclusions: While triple-exposure drug regimens have demonstrated improved outcomes, nearly half of the patients in this study received additional treatments beyond TCE and over 1/3 progressed to penta-exposure. Given the findings of this study, fundamentally new approaches are needed to close the gap and unmet medical need. [Table: see text]
Association between MUC5B mutation and prognosis across solid tumors.
Authors: Qun Zhao, Hong Zheng, Wei Duan, Chengcheng Li, Wenzhuan Xie, Guoqiang Wang, Yuzi Zhang, Yuezong Bai, Yingchun Zhou
Journal: Journal of Clinical Oncology (2020)

e13515 Background: MUC5B encodes Mucin 5B, which is a gel-forming mucin and a major constituent of mucus in the respiratory tract. Previous studies have revealed an increased expression of MUC5B in invasive mucinous adenocarcinoma (IMA) of the lung, indicating it may be involved in the tumorigenesis, and its family member MUC16, which encodes cancer antigen 125 (CA125), a biomarker for tumor diagnosis and the MUC16 mutation was reported to be associated with higher tumor mutation load, and a better survival outcomes in Gastric Cancer. However, the association between MUC5B mutation and prognosis has never been investigated in solid tumors. Methods: Whole-exome sequencing, RNA sequencing and clinical data for 27 types of solid tumors were downloaded from The Cancer Genome Atlas (TCGA). Associations between MUC5B mutation and prognosis were analyzed, and gene set enrichment analysis (GSEA) was used to investigate the underlying mechanism. Results: Among the 27 tumors, MUC5B mutation was associated with a superior disease specific survival (DSS) in Uterine Corpus Endometrial Carcinoma (UCEC) (HR, 0.32; 95% CI, 0.13-0.80; P = 0.01), Bladder Urothelial Carcinoma (BLCA) (HR, 0.43; 95% CI, 0.18-1.05; P = 0.06) and lung adenocarcinoma(LUAD) (HR, 0.44; 95% CI, 0.2-0.95; P = 0.03). MUC5B was also or tended to be associated with longer progression-free survival (PFS) and overall survival (OS) in UCEC (PFS: HR, 0.40; 95% CI, 0.23-0.70; P &lt; 0.001; OS: HR, 0.57, 95% CI 0.31-1.03, P = 0.06), BLCA (PFS: HR, 0.40; 95% CI, 0.19-0.86; P = 0.02; OS: HR 0.42, 95% CI 0.20-0.90, P = 0.02) and LUAD (PFS: HR, 0.63; 95% CI, 0.38-1.06; P = 0.08; OS: HR 0.55, 95% CI 0.31-0.97, P = 0.04). However, MUC5B mutation was associated with poorer OS (HR 1.64, 95% CI 1.03-2.59, P = 0.03) and tended to be associated with poorer PFS (HR 1.56, 95% CI 0.95-2.57, P = 0.08) in Head and Neck squamous cell carcinoma (HNSC). MUC5B mutation was not associated with survival in other tumors. MUC5B mutation was associated with a higher TMB in UCEC, BLCA and LUAD, and GSEA revealed prominent enrichment of signatures related to DNA repair in MUC5B mutation group, compared to MUC5B wide-type group in UCEC (FDR &lt; 0.05), BLCA (FDR &lt; 0.05), and LUAD (FDR &lt; 0.05), but not in HNSC. Conclusions: MUC5B mutation may be a potential predictor for better prognosis in UCEC, BLCA and LUAD, through potentiating DNA damage repair signaling. Identification of MUC5B mutation by genomic profiling provides a potentially novel and convenient approach for these patients to predict the prognosis, and refines patients' management in clinical practice.
A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study.
Authors: Masafumi Ikeda, Yoshitaka Inaba, Toshihiro Tanaka, Shunsuke Sugawara, Yoshihisa Kodama, Takeshi Aramaki, Hiroshi Anai, Shinichi Morita, Yoshinori Tsukahara, Hiroshi Seki, Mikio Sato, Kenya Kamimura, Kimei Azama, Masakatsu Tsurusaki, Eiji Sugihara, Masaya Miyazaki, Miyuki Sone, Yasuaki Arai
Journal: Journal of Clinical Oncology (2020)

4518 Background: Transarterial chemoembolization (TACE) with selective catheterization into the segmental or subsegmental hepatic arteries supplying HCC is often performed to achieve the complete local control of HCC in the patients with a limited number of small sized nodules. To clarify which of TACE with drug-eluting beads loaded with epirubicin (DEB-TACE) or conventional TACE with epirubicin-lipiodol (cTACE) can achieve the complete response (CR) more frequently, we performed a randomized controlled trial of DEB-TACE vs. cTACE. Methods: Between March 2016 and May 2019, unresectable HCC patients with Child-Pugh class A or B who were scheduled to receive selective TACE were randomly assigned 1:1 to the DEB-TACE group and the cTACE group. The primary endpoint was the CR rate at 3 months, and the secondary endpoints were the CR rate at 1 month and rate of adverse events (AEs). The response and AEs were assessed according to the modified RECIST by an independent review committee and the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0., respectively. Results: A total of 200 patients (DEB-TACE, 99 patients; cTACE 101 patients) were enrolled from 22 Japanese institutions. The patient characteristics were well-balanced between the two groups. The median number of tumors was one in both groups and the median tumor size was 20.0 mm in the DEB-TACE group and 20.5 mm in the cTACE group. The table shows the CR rates and frequencies of AEs. The CR rates of cTACE at 3 and 1 months were significantly higher than those of DEB-TACE. The frequency of AEs (all grades), including pyrexia, malaise, increased serum total bilirubin (T-Bil) and increased serum alanine transaminase (ALT), was significantly higher in the cTACE group than in the DEB-TACE group. Conclusions: Selective cTACE appeared to have greater efficacy for local tumor control as compared to selective DEB-TACE, however, the frequencies of post-embolization syndromes were higher in the cTACE group than in the DEB-TACE group. Clinical trial information: UMIN000021250 . [Table: see text]
Explanation of Errors in Population Numbers and Missing Data in Studies of Lifetime Skin Cancer Associated With Sexual Orientation and Gender Identity
Authors: Sean Singer, Elizabeth Tkachenko, Rebecca I. Hartman, Arash Mostaghimi
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Status of knowledge and performance of chronic heart failure guideline in general practitioners of Shanghai Pudong communities
Authors: Lan Ni, Hui Zhao, Jinhua Xue, Qi Xu
Journal: BMJ (2015)

Objective
To investigate the status of knowledge and performance on Chinese Heart Failure Diagnosis and Treatment Guideline (2014 version) in general practitioners of Shanghai Pudong communities.


Methods
The survey was conducted from April to June in 2014 with a self-designed questionnaire.Total 390 general practitioners (GPs) in Pudong New Area were selected by cluster sampling method.The contents of questionnaire included: diagnosis and differential diagnosis, drug therapy, non drug therapy of chronic heart failure.


Result
Total 385 questionnaires were retrieved with a response rate of 98.7% (385/390). The results showed that in aspect of diagnosis and differential diagnosis, 373(96.9%)Gps made the diagnosis based on history and physical examination, 171(44.4%)Gps never used BNP or NTPro-BNP tests, 280(72.7%)GPs did not know how to identify systolic or diastolic heart failure, 86(22.3%)Gps made the differential diagnosis according to the EF value.In aspects of drug therapy, the rate of beta blockers use was 10%-30% in 284(73.8%)Gps, 149(38.7%)Gps did not use beta blockers because of not knowing the contraindications, 289(75.1%)Gps used a maximum dose of betaloc for 25-50 mg, no one used 101-200 mg, 242(62.9%)Gps did not know the target dose of betaloc, the rate of ACEI/ARB use was 10%-30% in 330(85.7%)Gps, 258(67.0%)Gps would increase the dose but not knowing the target dose.The main reason for not using the target dose of Betaloc and ACEI/ARB was not knowing the dose.In aspect of non-drug therapy: 240(62.3%)Gps never heard of cardiac resynchronization therapy (CRT) and 271(70.4%)Gps never heard of implantable cardioverter defibrillator (ICD). The senior rank GPs grasped the guideline much better than Gps with primary and intermediate professional ranks.


Conclusion
General practitioners in community health centers should further study the guideline of heart failure, particularly need to strengthen the knowledge and ability of drug therapy.


Key words: 
Heart failure; Diagnosis; Treatment; General practitioner
Using real world data to examine outcomes in immunotherapy-treated patients with metastatic non-small cell lung cancer.
Authors: Sierra Luciano, Christian Haudenschild, Seth Kuranz
Journal: Journal of Clinical Oncology (2020)

e21715 Background: Important questions have been raised about whether real world data (RWD) can be relied upon to support clinical and regulatory decision-making. The aims of this study were to assess overall survival (OS), time-to-treatment (TTT), follow-up time, and treatment pathways in metastatic non-small cell lung cancer (mNSCLC) patients treated with programmed cell death protein 1 inhibitors (PD-1i). Methods: Two mNSCLC cohorts were identified in a US based EMR network. To explore treatment pathways, patients had to have an advanced (stage 3/4) diagnosis of NSCLC confirmed by a tumor registry record. A line of treatment (LOT) was defined as a PD-1i or chemotherapy taken within 30 days. OS, time to treatment, and follow-up time were also calculated. In another cohort patients had to have at least one PD-1i (pembrolizumab, nivolumab, durvalumab, or atezolizmab) and an oncology treatment within 3 months of an advanced stage diagnosis. OS was calculated using Kaplan-Meier analysis and stratified by time after nivolumab approval, quarter of PD-1i initiation, and line of therapy of first PD-1i. Patient characteristics were defined by ICD, CPT, LOINC, and RxNorm terminology. Results: Median overall survival was found to be 213 days (IQR 109, 425.25). In the treatment pathways analysis, 58.3% of patients started on a non-PD-1i chemotherapy as an initial line of treatment for mNSCLC. PD-1i was the most common second line treatment and 41.4% of patients who started on a non-PD-1i therapy switched to a PD-1i as their second line therapy. Median time from advanced diagnosis to PD-1i inhibitor initiation (9.6 months (IQR 3.45, 21.45)) and median structured follow-up times from advanced diagnosis (21.87 months (IQR 11.94, 38.97)) and from inhibitor initiation (8.71 months (3.06, 17.26)) were comparable to results found in other RWD. Conclusions: Overall survival, time to treatment, and other outcomes were consistent with comparable RWD sources, (Stewart M, 2019; Sean K 2018) regardless of treatment timeframe. We demonstrated that our real world evidence based approach provides a robust method for analyzing clinical outcomes, supporting the validity of real world data to complement clinical trials and inform clinical decisions.
外科治疗单侧侧脑室性脑积水14例
Authors: 蔡强, 刘仁忠, 陈谦学, 陈治标, 晏炳元, 简志宏, 徐海涛, 田道锋, 叶应湖, 王国安
Journal: BMJ (2005)

对我院自1990年至2004年收治的14例单侧侧脑室性脑积水患者分别采用脑室-腹腔分流术和神经内镜下透明隔造瘘术治疗.其中采用脑室-腹腔分流术4例,采用神经内镜透明隔造瘘术10例.所有病例均在术后2 d头痛、呕吐症状消失,记忆力下降者术后3 d好转,视力下降者术后1个月有所恢复.分流术组中出现分流管阻塞、术后发热各1例;内镜组中仅1例出现伤口愈合不良.随访0.5～14年,均神经功能恢复良好,无颅内高压症状,无癫痫再发作。
Ultrasonography versus nerve conduction study in diagnosis of patients with carpal tunnel syndrome
Authors: Feng-yuan Che, Liang-jun Jiang
Journal: BMJ (2012)

To compare the diagnostic value of high-resolution uhrasonography (HR-US) with nerve conduction study (NCS) in patients with clinically defined carpal tunnel syndrome (CTS),a prospective study was conducted on 37 consecutive patients investigated for sensory hand symptoms. With the clinical diagnosis of CTS as gold standard,NCS showed higher diagnostic sensitivity (80％) than ultrasound (61％) (P =0.047 ).The positive predictive value of HR-US for CTS was 100％.The results indicated that HR-US could be used as a screening method for majority of clinically suspected CTS patients and only for those with negative HR-US results.

Key words: 
Carpal tunnel syndrome; Ultrasound
A case of thrombocytopenia induced by intravenous injection of lipid emulsion
Authors: Linglong Xu, Zhelin Xia, Weiwei Yang
Journal: BMJ (2016)

脂肪乳注射液因具有高热量、含必需脂肪酸等优点，是临床常用肠外营养制剂之一。部分患者脂肪乳治疗后可能出现不良反应。脂肪乳注射液诱发的血小板减少临床较少见，报道1例中/长链脂肪乳注射液诱发血小板减少患者的临床资料，提高医务工作者对该病的认识。
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
Authors: Filippo de Marinis, Giuseppe Giaccone, Roy S. Herbst, Cristina-Marinela Oprean, Aleksandra Szczesna, Ioannis Boukovinas, Lucia Bonomi, Young-Chul Kim, Yvonne J. Summers, Takayasu Kurata, Kimberly Mayumi Komatsubara, Megan Chen, Yu Deng, Hiroshi Kuriki, Simonetta Mocci, See Phan, Jacek Jassem, David R. Spigel
Journal: Journal of Clinical Oncology (2020)

9594 Background: IMpower110 (NCT02409342) evaluated atezo (anti–PD-L1) monotherapy as 1L treatment in PD-L1–selected patients (pts) with metastatic NSCLC and met its primary endpoint with statistically significant and clinically meaningful OS benefit in TC3 or IC3 wild-type (WT; EGFR/ALK-negative) pts. PROs were prespecified endpoints to assess pt perspectives on overall clinical benefit. Methods: Pts were randomized 1:1 to receive atezo 1200 mg IV q3w (Arm A) or platinum-based chemo (Arm B; 4 or 6 21-day cycles). Arm B non-squamous pts received cisplatin (cis) 75 mg/m 2 or carboplatin (carbo) AUC 6 + pemetrexed 500 mg/m 2 IV q3w; Arm B squamous pts received cis 75 mg/m 2 + gemcitabine (gem) 1250 mg/m 2 or carbo AUC 5 + gem 1000 mg/m 2 IV q3w. PROs were assessed by the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and lung cancer module QLQ-LC13. Time to confirmed deterioration (TTD) in QLQ-LC13 lung cancer symptoms (secondary endpoint) and change from baseline (BL) in global health status (GHS), functioning and lung cancer symptoms (exploratory endpoints) were analyzed in TC3 or IC3-WT pts. Clinically meaningful change was defined as a ≥10-point deterioration from BL. Results: Completion rates at BL (atezo, n = 107; chemo, n = 98) were high in both arms for the QLC-C30 (90% atezo, 86% chemo) and the QLC-LC13 (89% atezo, 85% chemo), and remained &gt; 80% at most visits. Mean BL scores for GHS, physical functioning, and role functioning were moderate, symptom burden was low, and all were similar in both arms. No differences in TTD were seen between arms for cough (HR, 0.98; 95% CI: 0.48, 2.03), chest pain (HR, 1.02; 95% CI: 0.47, 2.22), dyspnea (HR, 0.96, 95% CI: 0.57, 1.60), and 3-symptom composite score (HR, 0.92; 95% CI: 0.59, 1.44). Mean change in physical function from BL to wk 42 was modestly improved with atezo and greater than or similar to chemo. No clinically meaningful worsening in dyspnea, cough or chest pain was seen with atezo vs chemo. Mean change in cough and chest pain from BL numerically improved immediately after start of treatment and was maintained to wk 48 with atezo. Fatigue and nausea/vomiting scores numerically improved immediately with atezo and were maintained to wk 48. Conclusions: QLQ-C30 and QLQ-LC13 completion rates were high at BL and most study visits. TTD of lung cancer-related symptoms was similar in both arms, indicating pts’ low BL symptom burden was maintained for a similar duration. Pts receiving atezo vs chemo sustained numerical improvements in physical function and no worsening in lung cancer-related symptoms. Clinical trial information: NCT02409342 .
Effects of nutritional education by "knowledge, attitude and behavior" on health improvement in patients with type 2 diabetes
Authors: 杨勤兵, 杨兆军
Journal: BMJ (2007)

目的 评价知信行营养教育对2型糖尿病患者健康促进的影响.方法 在教育大课堂选择2型糖尿病患者116例接受知信行营养教育干预,同时选择100例接受常规教育的患者作为对照组.以糖尿病相关营养知识、生化监测指标等作为观察指标,干预期限为6个月.结果 干预组中有98例完成随诊.干预组患者在糖尿病营养知识、营养素摄入量以及代谢指标等方面与对照组差异均有统计学意义.其中糖化血红蛋白分别为(6.1±0.9)%和(7.7±2.3)%(t=6.421,P＜0.01),血清甘油三酯水平分别为(1.9±0.8)mmol/L和(3.4±0.8)mmol/L(t=13.191,P＜0.01).结论 知信行营养教育坚持开展个体化治疗,使患者增进知识,改变对待营养治疗的态度,并进一步付诸行动,从而改善临床治疗效果,最终达到增进健康的目的 。